Belgium, Andorra and Bahamas have been added to the UK quarantine list – heres why – Leighton Buzzard Observer

Posted on by

Travellers arrivng in the UK from Belgium will now be required to quarantine for 14 days (Getty Images)

Travellers arriving in the UK from Belgium, the Bahamas and Andorra will be required to quarantine for 14 days.

The new measure comes into place from Saturday 8 August, except in Wales where the restriction is already in place.

The trio of countries follow Spain and Luxembourg in having a quarantine reimposed, with the Foreign and Commonwealth Office warning against all but essential travel to the three countries.

When do the measures get underway?

The Transport Secretary revealed the changes on Thursday night.

He tweeted: Data shows we need to remove Andorra, Belgium and the Bahamas from our list of [coronavirus] travel corridors in order to keep infection rates DOWN.

"If you arrive in the UK after 0400 Saturday from these destinations, you will need to self-isolate for 14 days."

Scottish Justice Secretary Humza Yousuf said there was a shared understanding between all home nations that the measures were required.

Wales have already implemented the quarantine restrictions.

The measures apply to anyone travelling through Belgium on their return from other European or World destinations.

Why have the measures been introduced?

Belgium has seen a rise in cases in recent weeks with data showing 27.8 new cases per 100,000 people compared to UKs 8.4.

The weekly case rate has spiked in The Bahamas at 77.8, while Andorra has seen a five-fold increase in cases since mid-July.

According to the Guardian measures could be introduced for France amid a rise in cases.

Are there any new travel corridors?

UK travellers have been told it is now safe to travel to Malaysia and Brunei following a significant dip in cases.

Vaughan Gething, the Welsh health minister said the public health risk posed by a decreasing prevalence was now low enough to open up a travel corridor to the southeast Asian countries.

More:

Belgium, Andorra and Bahamas have been added to the UK quarantine list - heres why - Leighton Buzzard Observer

Tor Browser 9.5.3 Download – TechSpot

Posted on by

Tor is a network of virtual tunnels that allows people and groups to improve their privacy and security on the Internet. It also enables software developers to create new communication tools with built-in privacy features. Tor provides the foundation for a range of applications that allow organizations and individuals to share information over public networks without compromising their privacy.

Note: You can also download the latest beta version, Tor Browser 10 Alpha 1 here.

Individuals use Tor to keep websites from tracking them and their family members, or to connect to news sites, instant messaging services, or the like when these are blocked by their local Internet providers. Tor's hidden services let users publish web sites and other services without needing to reveal the location of the site. Individuals also use Tor for socially sensitive communication: chat rooms and web forums for rape and abuse survivors, or people with illnesses.

Journalists use Tor to communicate more safely with whistleblowers and dissidents. Non-governmental organizations (NGOs) use Tor to allow their workers to connect to their home website while they're in a foreign country, without notifying everybody nearby that they're working with that organization.

Groups such as Indymedia recommend Tor for safeguarding their members' online privacy and security. Activist groups like the Electronic Frontier Foundation (EFF) recommend Tor as a mechanism for maintaining civil liberties online. Corporations use Tor as a safe way to conduct competitive analysis, and to protect sensitive procurement patterns from eavesdroppers. They also use it to replace traditional VPNs, which reveal the exact amount and timing of communication. Which locations have employees working late? Which locations have employees consulting job-hunting websites? Which research divisions are communicating with the company's patent lawyers?

A branch of the U.S. Navy uses Tor for open source intelligence gathering, and one of its teams used Tor while deployed in the Middle East recently. Law enforcement uses Tor for visiting or surveilling web sites without leaving government IP addresses in their web logs, and for security during sting operations.

Welcome Screen

Our old screen had way too much information for the users, leading many of them to spend great time confused about what to do. Some users at the paper experiment spent up to 40min confused about what they needed to be doing here. Besides simplifying the screen and the message, to make it easier for the user to know if they need to configure anything or not, we also did a 'brand refresh' bringing our logo to the launcher.

Censorship circumvention configuration

This is one of the most important steps for a user who is trying to connect to Tor while their network is censoring Tor. We also worked really hard to make sure the UI text would make it easy for the user to understand what a bridge is for and how to configure to use one. Another update was a little tip we added at the drop-down menu (as you can see below) for which bridge to use in countries that have very sophisticated censorship methods.

Proxy help information

The proxy settings at our Tor Launcher configuration wizard is an important feature for users who are under a network that demands such configuration. But it can also lead to a lot of confusion if the user has no idea what a proxy is. Since it is a very important feature for users, we decided to keep it in the main configuration screen and introduced a help prompt with an explanation of when someone would need such configuration.

As part of our work with the UX team, we will also be coordinating user testing of this new UI to continue iterating and make sure we are always improving our users' experience. We are also planning a series of improvements not only for the Tor Launcher flow but for the whole browser experience (once you are connected to Tor) including a new user onboarding flow. And last but not least we are streamlining both our mobile and desktop experience: Tor Browser 7.5 adapted the security slider design we did for mobile bringing the improved user experience to the desktop as well.

Other

What's New:

Tor Browser 9.5.3 is now available from the Tor Browser download page and also from our distribution directory. This release updates Firefox to 68.11.0esr, NoScript to 11.0.34, and Tor to 0.4.3.6.

Also, this release features important security updates to Firefox.

The full changelog since Tor Browser 9.5.1 is:

All Platforms

Note: We are aware of a bug that allows javascript execution on the Safest security level (in some situations). We are working on a fix for this. If you require that javascript is blocked, then you may completely disable it by:

The full changelog since Tor Browser 9.0.5 is:

All Platforms

Build System Windows

View original post here:

Tor Browser 9.5.3 Download - TechSpot

Experts taught us how to look for online extremism in Monterey County — and what we found is surprising. – Monterey County Weekly

Posted on by

The good news is that online extremism is not thriving in Monterey County as it is elsewhere in the country. The bad news is that corporate gatekeepers keep so much of whats happening on the internet private and proprietary that its impossible to be sure of the above.

TheWeeklyrecently reported on a new research team at the Middlebury Institute of International Studies that uses tech tools to track hate speech, incitement to violence, and how people get radicalized on the internet. As part of the Center on Terrorism, Extremism, and Counterterrorism, they are contributing to a growing field focused on turning the internet into a less dangerous place.

In the spirit of collaboration, CTEC Deputy Director Kris McGuffie and Digital Research Lead Alex Newhouse agreed to train theWeekly, providing a tutorial on how to search for online extremists tied to a certain geographic region, in this case, Monterey County.

The first thing to understand, Newhouse says, is the goals of the extremists on the internet. They want to radicalize as many people as possible, which means they must operate on mainstream social networks like Facebook or YouTube. These platforms have weaknesses that can be exploited, like the tendency of polarizing content to go viral.

After priming audiences with subtle messages of hate, extremists hope to recruit more people into their movement and they do so on niche online communities. They target individual users on video game forums, apps like Discord, or certain groups on Reddit.

Finally, extremists need to develop their groups identity, plan gatherings or demonstrations and eventually violent attacks. That activity happens in designated digital communities, with some known examples being Iron March, Stormfront, KiwiFarms and 8kun.

Each of these online spaces, from Facebook through 8kun, can be classified according to how easily accessible and searchable it is. Theres the regular internet, or Clearnet, which is indexed by search engines and is easy to navigate. The Grey Web refers to invite-only groups or spaces that you have to already know about to reach. The most hidden part of the internet is called the Dark Web. It will never show up on Google results and getting to it requires specialized software such as a Tor browser. The Dark Web is where child pornography is distributed, drug deals are conducted, and where neo-Nazis make plots.

After going over the basics, Newhouse talks about the methods of investigation. This tutorial is taking place on Zoom, so Newhouse begins sharing his screen. The first stop is Facebook where he quickly locates a certain politically focused page with Monterey County in its name. He scrolls down to reach the sidebar suggesting Related Pages. This sidebar is populated by a recommendation algorithm, which is one of the main ways regular users on innocuous pages get funneled toward extremist pages.

Facebooks recommendation algorithm is completely broken down, sending you to ever more extremist content, Newhouse says. Its like a rabbit hole of radicalization. YouTube has been shamed into changing a similar recommendation algorithm, but it remains in place on Facebook. Newhouse goes through a few Related Pages, but nothing alarming comes up.

Next up, Newhouse opens up a website calledIron March Exposed, a database of leaked posts from the now-defunct fascist chat platform Iron March. A keyword search for Monterey yields a post from May 20, 2015 by a user known only as Jakob. Jakob says hes 18 and finishing up high school somewhere in or near Monterey. He says hes an Eagle Scout and a Senior Patrol Leader and his goal is to become a U.S. Air Force pilot. Jakob is also well-read, and he rattles off his fascist credentials: My preferred authors are George Lincoln Rockwell, Julius Evola, Benito Mussolini and Machiavelli, and I have just started reading Mein Kampf, he writes. His classmates just never seemed to get it: I am joining because of the lack of like-minded people around me. I went into high school smoking weed, thinking race-mixing was fine and thinking gays were alright. To end his post, Jakob notes that he is very good at shooting. I grew up around firearms and have plenty of training with rifles and shotguns and handguns alike.

(Deputy Scout Executive Eric Tarbox says he searched the Boy Scouts database but could not identify any Eagle Scout or a Senior Patrol Leader with a matching age and name.)

After Iron March shut down, white supremacists migrated to Discord, among other places. And there was a leak from that platform as well, Newhouse says, while navigating to Discord Leaks, a database hosted by a media outlet called Unicorn Riot. Another place to hunt for hate speech is 4plebs.org, where conversations that took place on 4chan, an anonymous internet forum, are archived.

This type of work is quite manual, and extremism researchers are assisted by their accumulation of knowledge about memes, slang and violent ideologies. Clues such as user names and email addresses can sometimes be tracked and cross-checked on different platforms to discover more details about profiles of users.

But without too many concrete local results, Newhouse moves on another set of techniques those involving the collection of large amounts of data for further analysis. Relatively few social media companies make their data accessible for downloading by researchers and analysts. Examples of transparent companies with what are known as open APIs, or application programming interfaces include Twitter, Reddit and Telegram. (Facebook and Instagram, by contrast, do not allow data to be downloaded in bulk.)

After learning how to download as many as 18,000 tweets at a time, theWeeklywrote some of its own lines of code using the software language R. Every tweet posted over the past week or so and linked to a location within a 30-mile radius of Monterey Countys geographic center entered into a new dataframe. Next, theWeeklysearched the dataframe for certain polarizing terms and codewords, like #Obamagate and QAnon. Many of the resulting tweets were from ordinary people simply remarking on the news of the day. Some led to anonymous accounts like @LawlessBorders located in Freedom, USA and devoted to incendiary anti-immigrant rhetoric. The search also turned up a Santa Cruz resident by the name Justin Rothling. He is a proponent of the QAnon conspiracy theory, according to which a secret cabal of pedophiles within the U.S. government is plotting against President Donald Trump.

Its not always easy to classify online behavior as extremist, and a good example is the case of @DaveOv10, the not-so-well-hidden Twitter identity of Dave Overton, an associate professor of warfare of the Naval War College who teaches at the Naval Postgraduate School in Monterey. At least once, Overton promoted the #plandemic conspiracy theory, which serves to undermine public health efforts aimed at sopping Covid-19. He also a amplifies dangerous rhetoric by using hashtags #EnemyOfThePeople to attack the press. But his primary issue of concern appears to be the exoneration of Michael Flynn, Trumps former national security adviser.

The Michael Flynn cause overlaps with QAnon but is not the same thing, says Marc-Andr Argentino, who is conducting his doctoral research on the QAnon theory at Concordia University. The user probably navigates and consumes similar conservative root media as QAnon adherents, probably also consumes some conspiracy theory content based on his posts, Argentino says.

Overton declined an interview request, but writes by email that the opinions expressed were his and not of any government institution.

Do you want to join the mission to stop hate in Monterey County? A number of local groups make that part of their mission.

This story was edited to clarify that Dave Overton is an employee not of the Naval Postgraduate School but of the Naval War College.

Originally posted here:

Experts taught us how to look for online extremism in Monterey County -- and what we found is surprising. - Monterey County Weekly

Tor Browser Bundle – Free download and software reviews …

Posted on by

Pros

Good for privacy

Cons

Takes a little bit of understanding

Pros

There were no pros to this program.

Cons

After one search, the results came up empty. After re-installing, the results continued to come up empty.

There is NO UNINSTALL feature. I deleted the program directory and hope that it is actually gone from my computer!

Summary

Do not waste your time downloading this program. You will be disappointed and frustrated.

Pros

None. It's junk.

Cons

Forget this poorly designed piece of garbage. It just plain doesn't work and it's not supported.

The only website that loads is the "Tor Blog". Everything else returns a "bad gateway" message.

Forget about asking for help on the blog. Your "ask a question" message will be rejected because you didn't enter qualifying "tags". There's a link to suggested tags but they're all rejected too. Utterly useless.

I used the "Contact Us" form and they suggested using the "Ask a Question" button on the blog, even after I told them it didn't work because of the asinine "tags" requirement,.

Don't waste your time on this unsupported crap.

Summary

=

Pros

This is really a no brainer is you want to browse anonymously

Cons

can be slow at times but no big deal

Pros

Excelent Project :)Some popular but not easy to find Onion Links:

Hidden Wiki hiwiki544q5q4gbt.onionUncensored Hidden Wiki uhwiki36pbooodfj.onionAlphaBay alphabay54qdm7bn.onionNucleus nucleus4owfwglww.onionSilkRoad V3 reloadxuwmn4gkbe.onion

Cons

i think there is nothing bad about it

Pros

-Reliable-Privacy is great-Secure

Cons

-Slow at times

Pros

Obvious HUGE pros long as one is careful and does there research before using Tor. Im using it solely to get around web filtering at work. GOOD JOB to the folk who decided to not try because they get spooked. Stay smart until your ready for Tor 🙂

Cons

Can cause some problems, just dont be stupid ; )

Summary

Like privacy? Like going around your work places Blocker? This is the thing for you!

Pros

Greate software!

Cons

Greate software!

Pros

It is kind of a cool search tool with apps and much to read and discover. Some of the content is not accessed on the regular web and that is both a blessing for surfers and a curse for TOR's administration, I would think. TOR's administration must have their hands full putting out fires as some of the websites have been raided by the FBI apparently. I'll leave the discussion at that point and leave it to those who wish to research more on the specifics.

Cons

For the average Internet user or just to surf the web, using TOR is fraught with too many warnings about turning off plug ins and many other things people normally do and the reason is security so that you will not break privacy and reveal your IP address, etc. But trying it is a different experience and a lesson in Internet security to some extent.

Summary

The surfing experience lacks the ease and shine of the regular Internet. It is good for users who are concerned about their privacy to quite an extent such as Wikileaks contributors or whistle blowers or if you are in a witness protection program somewhere. Seriously.

Pros

Lets you browse internet without government trying to get up your ass and without companies trying to track everything you do so they can get you to watch their ads to make half a penny off of you. I hate how so many companies wouldnt mind wasting a day of your life to get a few cents from advertising. Its disgusting

Cons

Are none if you download real tor. Its a simple browser and less invasive than any other I know. As in, its not in the battle between firefox, chrome and explorer to become your default browser. Tor is just there when you need it, and stays out of your face completely unless you need it.

https://www.torproject.org/download/download.html.en

Summary

Bing is probably the worst search engine out there. I believe it accepts payments in return for higher placing on the search result so its no wonder that some bullshizz sites come up before the real site when using bing. i tried to download first search result and it was CLEARLY not the real tor but some cookie/virus.

Please Wait

Read the original:

Tor Browser Bundle - Free download and software reviews ...

Avacta extends partnership with Daewoong Pharmaceutical and AffyXell Therapeutics for Covid-19 stem cell treatments – Cambridge Independent

Posted on by

Avacta has extended its collaboration and license agreement with Daewoong Pharmaceutical Co and their South Korean joint venture AffyXell Therapeutics.

They will develop stem cell treatments incorporating Avactas neutralising Affimer therapy for the treatment of seriously ill patients with Covid-19 and prepare for the rapid development of similar therapies for future global pandemics.

Stem cell therapies offer one potential route to repairing lung tissue damage caused by the immune systems over-reaction to respiratory diseases such as Covid-19.

AffyXell Therapeutics, a next-generation cell and gene therapy joint venture between Whittlesford-based Avacta and Daewoong, is developing mesenchymal stem cell (MSC) treatments engineered to produce Affimer therapies in the patient at the site of action.

The partnership has been extended to include Affimer molecules that target viruses, such as coronaviruses, to develop therapies that repair lung damage, while also producing neutralising Affimer molecules to prevent the progression of the disease.

Under the expanded partnership, AffyXell will engineer mesenchymal stem cells to express SARS-CoV-2 neutralising Affimer molecules to develop treatments for seriously ill Covid-19 patients. It will also prepare for rapid development of next-generation stem cell therapies for future infectious respiratory disease outbreaks.

Avacta CEO Dr Alastair Smith said: I am very pleased to have extended our collaboration and license agreement with Daewoong Pharmaceutical to include the SARS-CoV-2 neutralising Affimer molecules for the treatment of Covid-19 and to create the potential to respond very rapidly in future to global virus threats.

AffyXell will address the need over the coming years for advanced stem cell therapies to treat lung damage caused by cytokine release syndrome suffered by Covid-19 patients and, at the same time, help prevent disease progression in these patients through the action of a neutralising Affimer therapy.

More broadly, one of the key areas of unmet clinical need that AffyXell can address with its next-generation mesenchymal stem cell therapies is acute pulmonary diseases such as COPD and acute respiratory distress syndrome. We, and our partners in South Korea, are very excited by the potential to develop life improving treatments for patients with these serious respiratory diseases as well as Covid-19.

Seng-ho Jeon, CEO of Daewoong Pharmaceutical and AffyXell Therapeutics, said:

It is very encouraging that AffyXell now has the opportunity to expand the application of its next-generation stem cell platform technology to target viruses. The SARS-CoV-2 neutralising Affimer to be developed in combination with AffyXells cell and gene technology is expected to be an innovative solution for COVID-19 patients suffering cytokine release syndrome.

Daewoong has been also conducting several research programs and clinical trial for Covid19. As the Covid-19 crisis has caused great difficulties worldwide, we will continue to focus our efforts to develop a novel therapeutic agent for Covid-19.

Read more

Covid-19 test developed by Avacta and Adeptrix to be evaluated by governments CONDOR programme

Avacta and Integumen collaborate to detect Covid-19 in sewage

Avacta signs distribution deal for Covid-19 self-test under development

Avacta confirms Affimer reagents prevent infection of human cells in model of Covid-19 virus

The rest is here:

Avacta extends partnership with Daewoong Pharmaceutical and AffyXell Therapeutics for Covid-19 stem cell treatments - Cambridge Independent

Three Years After Stem Cell Trial for Heart Failure was Abandoned New Evidence Shows it Works – Diagnostic and Interventional Cardiology

Posted on by

August 4, 2020 - More than three years after a clinical trial was prematurely ended for failing to show progress in healing heart attack scars, the European Heart Journal publishing some surprising results showing that the heart cell treatment does benefit patients.[1]

Data from the ALLSTAR study published Tuesday by the European Heart Journal showed that although infusions of allogeneic cardiac cells (called cardiosphere-derived cells or CDCs) did not appear to shrink the infarct scar after a heart attack, other data from the study show a clear benefit.

Compared with patients who received placebo treatment, patients randomized to receive CDC infusions showed a decrease in the volume of blood in the heart before and after it beats, indicating that the heart had not dilated, as it does progressively in heart failure.

"As it develops heart failure, the heart gets bigger and bigger, like a swelling balloon," said the study's lead author, Raj Makkar, M.D., vice president of cardiovascular innovation and intervention for Cedars-Sinai and the Stephen R. Corday, M.D., chair in interventional cardiology. "One way we can measure the health of a heart is to measure the volume of blood it can hold. The bigger the volume, the more damaged the heart."

The newly analyzed data from the ALLSTAR study, which was sponsored by Capricor Therapeutics, showed that patients given a placebo had hearts that continued to swell, holding larger volumes of blood, while the patients who received CDC infusions had smaller hearts with lower volumes.

The new data results include:

The volume of blood held by the heart was essentially unchanged six months after CDC infusion, but increased by more than a teaspoonful in placebo patients.

A blood protein that measures heart failure severity was reduced in patients who had received CDCs, but not in placebo patients.

The chance that these findings were statistical flukes was only 2 percent.

"To me, these data are very reassuring that there really is therapeutic benefit," said Eduardo Marbn, M.D., Ph.D., executive director of the Smidt Heart Institute. "There is a growing body of evidence that this cell treatment does work."

Results from the earlier CADUCEUS trial, published in The Lancet in 2014, showed that injecting CDCs into the hearts of heart attack survivors significantly reduced infarct size. In 2017, however, the multicenter ALLSTAR study was prematurely halted after six months of data showed no decrease in heart attack scar size, but later analyses revealed the beneficial findings reported here.

"We think we may have chosen the wrong endpoint," said Marbn, the Mark S. Siegel Family Foundation Distinguished Professor, whose discoveries and technologies resulted in CDCs. "This happens in science because you have to design the trial a year or more before you begin, and sometimes you bet on the wrong hors... but that doesnt necessarily mean the therapy is ineffective."

The cells used in the study were CAP-1002, Capricor Therapeutics off-the-shelf, cardiosphere-derived cell (CDC) product candidate. Other clinical trials and case series, in which CDCs were used to treat advanced heart failure, Duchenne Muscular Dystrophy, and COVID-19, also demonstrated positive results. And new studies using CDCs are in the planning stages.

"California is known as the stem cell state, but few technologies being tested in California actually were developed here," said Shlomo Melmed, MB, ChB, executive vice president of Academic Affairs, dean of the Medical Faculty and professor of Medicine. "Increasing evidence-including the results of the large multicenter ALLSTAR trial-validates the potential utility of a cell product which was conceived by a faculty member at Cedars-Sinai, and first tested clinically here."

Read the complete study published by the European Heart Journal.

Disclosures: Except for the cells used in CADUCEUS, the cardiosphere-derived cells used in these studies were derived from donor hearts and provided by Capricor Therapeutics. Marbn developed the process to grow CDCs when he was on the faculty of Johns Hopkins University; the process was further developed at Cedars-Sinai. Capricor has licensed the process from Johns Hopkins and from Cedars-Sinai for clinical and commercial development. Capricor has licensed additional intellectual property from Cedars-Sinai and the University of Rome. Cedars-Sinai and Marbn have financial interests in Capricor.

Reference:

1. Raj R Makkar, Dean J Kereiakes, Frank Aguirre, et al. Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial. European Heart Journal, ehaa541, https://doi.org/10.1093/eurheartj/ehaa541.

Link:

Three Years After Stem Cell Trial for Heart Failure was Abandoned New Evidence Shows it Works - Diagnostic and Interventional Cardiology

IMAC Holdings Receives FDA Authorization to Initiate Clinical Study of Its Umbilical Cord-Derived Allogenic Mesenchymal Stem Cells for the Treatment…

Posted on by

BRENTWOOD, Tenn., Aug. 05, 2020 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (the Company or IMAC), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announced the United States Food and Drug Administration (the FDA) approved its investigational new drug application, which IMAC submitted in May 2020, for the use of umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia, or the gradual loss and slowing down of spontaneous body movement, due to Parkinsons disease.

The Company will now initiate enrollment of 15 patients for its Phase 1 trial to evaluate the safety and tolerability of the stem cell product acquired from technology developed by a major research university to treat patients with Bradykinesia due to Parkinsons utilizing intravenous administration of Whartons jelly-derived mesenchymal stem cells. The Company believes that the causes of bradykinesia may be related to an inflammatory response in the body. The Companys new study is designed to confirm this belief and support the Companys long-term strategy for the use of regenerative medicine in combination with physical rehabilitation to reduce the effect of movement-restricting diseases.

Our regenerative rehabilitation centers have long focused on the importance of finding and applying non-opioid, non-surgical solutions to physical ailments in orthopedics. In 2017, our neurosurgeon researched opportunities to apply stem cells to treating Parkinsons, and we put a team together to design a treatment for our neurological patients that simply could not achieve maximum benefit from physical therapy alone, commented Jeffrey Ervin, IMACs Chief Executive Officer. Having received approval to proceed with our study, IMAC is extremely optimistic regarding the potential of this stem cell technology. This has the potential to not only expand proprietary service options for neurological patients, but also advance the way physically debilitating inflammatory conditions are managed as a whole. We would like to thank the FDA for the collaborative process and the partners who helped us achieve this milestone, including patient advocate, Doug Oliver and his team at Regenerative Outcomes.

The Phase 1 trial will consist of three treatment protocols: five patients with bradykinesia due to Parkinsons will receive a low dose intravenous infusion of stem cells, five patients will receive a medium dose intravenous infusion of stem cells and five patients will receive a high dose intravenous infusion of stem cells. The Phase 1 trial will be conducted over 12 months to determine the incidence and extent of adverse events, although the Company will also investigate the efficacy of its stem cell treatment. More information on the clinical trial, including patient criteria, can be found on clinicaltrials.gov.

IMAC will enroll participants from its existing clinics in Illinois, Tennessee, Kentucky and Missouri in its Phase 1 trial. Prospective enrollees may email fdatrial@imacregeneration.com to be considered for the trial. IMACs medical doctors and physical therapists have been trained to administer the treatment and manage the therapy for the clinical trial, which is anticipated to begin in 30 days.

About IMAC Holdings, Inc.

IMAC Holdings was created in March 2015 to expand on the footprint of the original IMAC Regeneration Center, which opened in Kentucky in August 2000. IMAC Regeneration Centers combine life science advancements with traditional medical care for movement restricting diseases and conditions. IMAC owns or manages 16 outpatient clinics that provide regenerative, orthopedic and minimally invasive procedures and therapies. It has partnered with several active and former professional athletes, opening six Ozzie Smith IMAC Regeneration Centers, two David Price IMAC Regeneration Centers, as well as Mike Ditka IMAC Regeneration Centers and a Tony Delk IMAC Regeneration Center. IMACs outpatient medical clinics emphasize its focus around treating sports and orthopedic injuries and movement-restricting diseases without surgery or opioids. More information about IMAC Holdings, Inc. is available at http://www.imacregeneration.com.

# # #

Safe Harbor Statement

This press release contains forward-looking statements. These forward-looking statements, and terms such as anticipate, expect, believe, may, will, should or other comparable terms, are based largely on IMAC's expectations and are subject to a number of risks and uncertainties, certain of which are beyond IMAC's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the skills and experience necessary to meet customers requirements, and its ability to protect its intellectual property. IMAC encourages you to review other factors that may affect its future results in its registration statement and in its other filings with the Securities and Exchange Commission. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this press release will in fact occur.

IMAC Press Contact: Laura Fristoelfristoe@imacrc.com

IMAC Investor Contact:Bret Shapiro(516) 222-2560brets@coreir.com

Source: IMAC Holdings, Inc.

View post:

IMAC Holdings Receives FDA Authorization to Initiate Clinical Study of Its Umbilical Cord-Derived Allogenic Mesenchymal Stem Cells for the Treatment...

Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market 2020 Size by Product Analysis, Application, End-Users, Regional Outlook,…

Posted on by

New Jersey, United States,- Market Research Intellect aggregates the latest research on Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market to provide a concise overview of market valuation, industry size, SWOT analysis, revenue approximation, and regional outlook for this business vertical. The report accurately addresses the major opportunities and challenges faced by competitors in this industry and presents the existing competitive landscape and corporate strategies implemented by the Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies market players.

The Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies market report gathers together the key trends influencing the growth of the industry with respect to competitive scenarios and regions in which the business has been successful. In addition, the study analyzes the various limitations of the industry and uncovers opportunities to establish a growth process. In addition, the report also includes a comprehensive research on industry changes caused by the COVID-19 pandemic, helping investors and other stakeholders make informed decisions.

Key highlights from COVID-19 impact analysis:

Unveiling a brief about the Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies market competitive scope:

The report includes pivotal details about the manufactured products, and in-depth company profile, remuneration, and other production patterns.

The research study encompasses information pertaining to the market share that every company holds, in tandem with the price pattern graph and the gross margins.

Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market, By Type

Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market, By Application

Other important inclusions in the Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies market report:

A brief overview of the regional landscape:

Reasons To Buy:

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Non-Thermal Pasteurization Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Artificial Intelligence in Manufacturing Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Hybrid Fiber Coaxial Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Steel Fiber Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

End User Experience Monitoring Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Original post:

Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market 2020 Size by Product Analysis, Application, End-Users, Regional Outlook,...

Strathmore man with MS calls for more Canadian treatment alternatives – CTV Toronto

Posted on by

CALGARY -- Hes just 49 years old and already his mobility is mostly confined to his right hand. If Chad Tashlikowich can halt the progression of his primary-progressive Multiple Sclerosis there, hell consider it a victory.

In 2014 Tashlikowich crowd-funded an $80,000 stem cell treatment in Russia hoping to keep him out of an electric wheel chair. That therapy was unsuccessful.

It really hasnt changed the trajectory at all, he says. Despite the risks and expense, his health didnt improve. Its really poor. Its kinda gone down hill really ever since. I dont think the stem cells did a lot,

Now he wants to try a drug treatment ocrevus recommended to him by American Dr Aaron Boster who specializes in MS, a disease that attacks the central nervous system. The problem is, in Canada the drug is not approved for use on patients with Tashlikowichs form of the disease.

You have a mechanic for your car. And if he doesnt do a good job you get another one. You cant do that with a neurologist, Tashlikowich says.

Dr Luanne Metz is a neurology professor at the University of Calgary. Addressing overseas stem cell transplants, she says she understands how MS patients can see some of the treatments as worth the expense and the risk, given their dire prognoses. But she cautions that not all foreign treatment is what its advertised to be, and even when it is, there are medical reasons why guidelines are what they are in Canada.

The problem is, that when people go outside the country for unapproved therapies, they are often not in regulated situations, says Dr. Metz, adding that stem cell therapy does not help primary-progressive MS. She was not speaking about the efficacy of the drug Ocrevus.

Health Canada regulates drug approvals through a rigorous process. Its up to individual provinces to adopt approved treatments from there.

Go here to see the original:

Strathmore man with MS calls for more Canadian treatment alternatives - CTV Toronto

Wave of New Therapies Improve Outcomes for Patients with Multiple Myeloma – Dana-Farber Cancer Institute

Posted on by

For many patients with multiple myeloma, a new generation of drugs and drug combinations is producing better outcomes and fewer side effects. In recent months, several novel therapies studied and tested by Dana-Farber scientists have gained approval from the U.S. Food and Drug Administration (FDA) or taken a step toward approval after posting solid results in clinical trials.

The drugs are the fruit of years of research into improving treatment for multiple myeloma, a cancer of white blood cells known as plasma cells in the bone marrow. Many of the new agents are biologically derived made from substances such as proteins and antibodies found in living things and target biological mechanisms in a very specific, targeted fashion. Dana-Farber researchers have played a key role in these efforts.

These are each powerful examples of how next-generation novel therapies translated here at Dana-Farber from bench to bedside are further improving outcomes for our patients, and at a remarkable pace, says Paul G. Richardson, MD, clinical program leader and director of clinical research at the Jerome Lipper Multiple Myeloma Center at Dana-Farber.

Following a Dana-Farber-led clinical trial, the FDA recently approved the novel drug isatuximab in combination with pomalidomide and dexamethasone for adults with relapsed or refractory (non-responsive) myeloma who have received at least two prior therapies, including lenalidomide and drugs known as proteasome inhibitors. The drug went into trials after laboratory work by Dana-Farbers Yu-Tzu Tai, PhD, and Kenneth Anderson, MD, showed it was active against myeloma cells. In the clinical trial, the three-drug combination lowered the risk that the disease would progress by 40%, compared to pomalidome and dexamethasone alone.

Dana-Farber investigators conducted laboratory research and led the first clinical trial of the drug melflufen plus dexamethasone in patients with relapsed or refractory myeloma. Melflufen is a peptide conjugate drug made of a stub of protein, or peptide, joined to a chemotherapy agent and delivers a toxic payload directly to myeloma cells in a selective, time-sparing approach.

Results from an early-phase clinical trial published in Lancet Oncology showed the drug is active in patients with myeloma and is safe at recommended doses. Unlike the previously used standard drug melphalan, it doesnt cause mucositis inflammation of membranes within the digestive tract or hair loss. The results prompted investigators to launch two larger trials, some of whose results are being processed and are due to be published soon.

In a major study published in Blood, Dana-Farber researchers and their associates found that in patients newly diagnosed with myeloma who are eligible for a stem cell transplant, adding the drug daratumumab to the standard three-drug regimen produced more responses, and deeper responses, than in patients receiving the three-drug therapy alone.

Dana-Farber researchers were involved in the development and initial testing of the drug belantamab mafodotin, which has shown considerable promise in clinical trials and has been granted priority review for approval by the FDA.

An antibody conjugate drug consisting of an antibody that specifically targets myeloma cells and an agent that disrupts cell division, its use was informed by a preclinical trial at Dana-Farber involving Yu-Tzu Tai, PhD, and Kenneth Anderson, MD. Balantamab mafodotin was tested in studies led by Paul Richardson, MD, in patients with relapsed or refractory multiple myeloma whose disease continued to worsen after a stem cell transplant, chemotherapy, or other treatment. In the DREAMM-1 and -2 trials, the drug showed strong anti-myeloma activity with manageable side effects.

After certification in Internal Medicine, Hematology and Medical Oncology, as well as working in Cancer Pharmacology from 1994 onwards at Dana-Farber Cancer Institute (DFCI), Dr. Paul Richardson joined the Jerome Lipper Myeloma Center in 1999, was appointed Clinical Director in 2001, and led the development of several first-generation novel drugs including bortezomib, lenalidomide and pomalidomide for the treatment of multiple myeloma. Subsequent studies have focused on next-generation novel drugs including panobinostat and second-generation proteasome inhibitors including ixazomib. More recently, his clinical innovations have been in the development of the breakthrough monoclonal antibodies elotuzumab and daratumumab for the treatment of both untreated and relapsed myeloma, as well as isatuximab and more broadly, antibody drug conjugates including belantamab mafodotin, as well as other immunotherapeutic strategies. In addition to these agents, he is leading the development of melflufen, a targeted cytotoxic and an first-in-class small molecule inhibitor selinexor, which inhibits XPO-1, a key nuclear export protein, as well as first-in-human studies of cereblon E3 ligase modulators (so called CELMoDs) for the treatment of relapsed and refractory myeloma.

Over the last decade, his major effort has been focused on the development of lenalidomide, bortezomib and dexamethasone (so-called RVD), and its incorporation as part of the Intergroup Francophone Myelome (IFM)/DFCI clinical trial in newly diagnosed patients eligible for stem cell transplant treated with RVD. This regimen has generated an unprecedented response rate, leading to its adoption in this international study, as well as others in the United States and elsewhere. This particular trial incorporates genomic and proteomic evaluation to establish a future platform for tailored therapy and the optimal positioning of stem cell transplant, with results anticipated in 2021-22. Furthermore, RVD has been established as a backbone to which next-generation agents are being added, including elotuzumab, daratumumab and isatuximab, as well as panobinostat.

He has published extensively, having authored or co-authored over 400 original articles and 330 reviews, chapters, and editorials in peer-reviewed journals. In addition to holding positions on the Editorial Boards of leading journals, he is prior Chairman of the Multiple Myeloma Research Consortium (MMRC), Clinical Trials Core, a position held for 5 years as part of a rotating tenure, and for which he continues as a member of the Steering and Project Review Committee. He was also a member of ASCO Hematologic Malignancies Subcommittee for the required one-year term, and then for one year on the ASCO Internet Cancer Information Committee during 2017. He was appointed Chair of the Alliance Myeloma Committee in 2011 and continues in this role.

Honors include the George Canellos Award for Excellence in Clinical Research and Patient Care, and The Tisch Outstanding Achievement Award for Clinical Research, as well as an honorary Fellowship of the Royal College of Physicians (UK), given in recognition for international contributions in multiple Myeloma and stem cell transplantation. He was a co-recipient of the prestigious Warren Alpert Foundation Prize in recognition of the successful therapeutic targeting of the ubiquitin-proteasome pathway in 2012. He was also a co-recipient of the Accelerator Award for contributions to clinical research and patient enrollment in MMRC studies, as well as for the Research Center of the Year Award in 2009, followed by the second award for Center of the Year in 2017. He was ranked by Thomson Reuters Science Watch amongst the top 19 investigators at DFCI for the most highly cited research in 2016. He was the co-recipient of the ASH Ernest Beutler Prize for clinical science and translational research in the development of proteasome inhibition as an effective treatment strategy for multiple myeloma in 2015; the COMY Award for MM research (Paris, France) in 2016, and the prestigious IMF Robert A. Kyle Lifetime Achievement Award in 2017, and the Morse Research Award in 2019.

Read more:

Wave of New Therapies Improve Outcomes for Patients with Multiple Myeloma - Dana-Farber Cancer Institute

Adipose Derived Stem Cell Therapy Market: Technological Advancement & Growth Analysis with Forecast to 2026 – Chelanpress

Posted on by

Market Study Report has added a new report on Adipose Derived Stem Cell Therapy market that provides a comprehensive review of this industry with respect to the driving forces influencing the market size. Comprising the current and future trends defining the dynamics of this industry vertical, this report also incorporates the regional landscape of Adipose Derived Stem Cell Therapy market in tandem with its competitive terrain.

This Adipose Derived Stem Cell Therapy market report is an integrated document combining a detailed analysis of the industry in question. Combining an in-depth evaluation of this business sphere, the report is also inclusive of an elaborate industry segmentation that contains information about the various segments of the Adipose Derived Stem Cell Therapy market.

Request a sample Report of Adipose Derived Stem Cell Therapy Market at:https://www.marketstudyreport.com/request-a-sample/2695267?utm_source=chelanpress.com&utm_medium=SK

Additionally, the report is inclusive of a detailed outline of this business in tandem with the markets current size and status. Also, the volume and profit parameters have been overviewed in the study. Some pivotal insights pertaining to the regional frame of reference and the competitive spectrum of this industry have been enumerated in the study.

A generic scope of the Adipose Derived Stem Cell Therapy market:

A generic understanding of the competitive landscape

.

Ask for Discount on Adipose Derived Stem Cell Therapy Market Report at:https://www.marketstudyreport.com/check-for-discount/2695267?utm_source=chelanpress.com&utm_medium=SK

An all-inclusive understanding of the geographical terrain:

A brief summary of the segmentation:

.

.

For More Details On this Report: https://www.marketstudyreport.com/reports/covid-19-impact-on-global-adipose-derived-stem-cell-therapy-market-size-status-and-forecast-2020-2026

Related Reports:

1. Global Ursodeoxycholic Acid API Market Insights and Forecast to 2026Read More: https://www.marketstudyreport.com/reports/global-ursodeoxycholic-acid-api-market-insights-and-forecast-to-2026

2. Global Wound Cleaning Products Market Insights and Forecast to 2026Read More: https://www.marketstudyreport.com/reports/global-wound-cleaning-products-market-insights-and-forecast-to-2026

Related Report : https://www.marketwatch.com/press-release/underwater-pelletizer-market-analysis-growth-by-top-companies-expected-49-cagr-to-hit-2288-million-by-2026-2020-08-07

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Originally posted here:

Adipose Derived Stem Cell Therapy Market: Technological Advancement & Growth Analysis with Forecast to 2026 - Chelanpress

ASCO Expert on the Possible Benchmark Analysis of Autologous Transplantation in B-Cell Lymphomas – Cancer Network

Posted on by

Nirav Niranjan Shah, MD, discussed the analysis of autologous transplantation use in patients with relapsed, chemosensitive DLBCL and how it may become a comparator for other clinical trials.

In a data analysis presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Meeting, investigators analyzed whether the use of autologous stem cell transplant in patients with relapsed, chemosensitive DLBCL should remain the standard of care in the CAR T-cell era.

Based on the results of the analysis, it was suggested that autologous transplantation should remain the current standard of care in this patient population.

In an interview with CancerNetwork, Nirav Niranjan Shah, MD, of the Medical College of Wisconsin, spoke about how this analysis could potentially be a benchmark for future studies.

Transcription:

So, we hope to publish our analysis and get it into a peer reviewed journal, so that it becomes available and I think this will be a study that becomes a benchmark that can then be used as a comparator for other clinical trials. I think this gives us a very interesting viewpoint of contemporary data, were PET-CT was used, which is often, you know, a lot of older studies don't utilize PET-CT. So, I think this will be a study that's a benchmark and can be used as a comparison to new therapies that are coming down the road. Because, you know, since, you know, 1980s 1990s, autologous transplant has been that standard of care for relapsed aggressive B-cell lymphoma. And this supports that it should remain that. But it's also possible that over time new therapies do improve upon autologous transplant. But I think this trial will be a nice sort of benchmark to use for future studies.

Excerpt from:

ASCO Expert on the Possible Benchmark Analysis of Autologous Transplantation in B-Cell Lymphomas - Cancer Network

Cell Therapy Market: Study Navigating the Future Growth Outlook | Osiris Therapeutics, NuVasive, Vericel Corporation – Chelanpress

Posted on by

Cell Therapy Industry Report focuses on Market Influence Factors, Growth Drivers, Restraints, Trends and Opportunities so that Market Players can face any challenges and take advantage of Lucrative Prospects available in the Global Cell Therapy market.

The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries including Medical Device, Pharmaceutical, Healthcare and many more. Trade barriers are further restraining the demand- supply outlook. As government of different regions have already announced total lockdown and temporarily shutdown of industries, the overall production process being adversely affected; thus, hinder the overall Cell Therapy Market globally. This report on Cell Therapy Market provides the analysis on impact on Covid-19 on various business segments and country markets. The report also showcase market trends and forecast to 2027, factoring the impact of Covid -19 Situation.

Request Sample Copy of Cell Therapy Market at: https://www.theinsightpartners.com/sample/TIPRE00009666/

The Emerging Players in the Cell Therapy Market includes Kolon TissueGene, Inc., MEDIPOST, JCR Pharmaceuticals Co. Ltd., Stemedica Cell Technologies, Inc., Osiris Therapeutics, Inc., NuVasive, Inc., Fibrocell Science, Inc., Vericel Corporation, Cells for Cells, Celgene Corporation, etc.

Cell Therapy Market Definitions and Overview:

Cell therapy (CT) is the process of transplanting human cells to replace or repair damaged tissue or cells. Various methods can be used to carry out cell therapy. For instance, hematopoietic stem cell transplantation, also known as bone marrow transplant, is the most widely used cell therapy. It is used to treat a variety of blood cancers and blood-related conditions.

Cell therapy market is expected to grow due to factors such as increasing the biotechnology industry, rising healthcare expenditure, growing incidences of chronic diseases, and others. The market is expected to have growth opportunities in the emerging region as they are developing their genetic sectors rapidly.

The research provides answers to the following key questions:

Competitive scenario:

The study assesses factors such as segmentation, description, and applications of Cell Therapy industries. It derives accurate insights to give a holistic view of the dynamic features of the business, including shares, profit generation, thereby directing focus on the critical aspects of the business.

Scope of the Report

The research on the Cell Therapy market focuses on mining out valuable data on investment pockets, growth opportunities, and major market vendors to help clients understand their competitors methodologies. The research also segments the Cell Therapy market on the basis of end user, product type, application, and demography for the forecast period 20212027. Comprehensive analysis of critical aspects such as impacting factors and competitive landscape are showcased with the help of vital resources, such as charts, tables, and infographics.

Cell Therapy Market Segmented by Region/Country: North America, Europe, Asia Pacific, Middle East & Africa, and Central & South America

Major highlights of the report:

All-inclusive evaluation of the parent market

Evolution of significant market aspects

Industry-wide investigation of market segments

Assessment of market value and volume in past, present, and forecast years

Evaluation of market share

Study of niche industrial sectors

Tactical approaches of market leaders

Lucrative strategies to help companies strengthen their position in the market

Interested in purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPRE00009666/

Thanks for reading this article; you can also customize this report to get select chapters or region-wise coverage with regions such as Asia, North America, and Europe.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email: [emailprotected]

Continued here:

Cell Therapy Market: Study Navigating the Future Growth Outlook | Osiris Therapeutics, NuVasive, Vericel Corporation - Chelanpress

Personalized Cell Therapies Market to Show Incredible Growth by 2025 – Owned

Posted on by

Personalized Cell Therapies MarketInsights 2020 is an expert and top to bottom investigation on the momentum condition of the worldwide Personalized Cell Therapies industry with an attention on the Global market. The report gives key insights available status of the Personalized Cell Therapies producers and is an important wellspring of direction and course for organizations and people keen on the business. By and large, the report gives an inside and out understanding of 2020-2025 worldwide Personalized Cell Therapies market covering extremely significant parameters.

Request Free Sample copy of this report athttps://www.precisionbusinessinsights.com/request-sample?product_id=17290&utm_source=cole&utm_medium=24

Key Players in Personalized Cell Therapies Market arePCT Cell Therapy Services, LLC (U.S),S. Stem Cell, Inc. (U.S),Bellicum Pharmaceuticals, Inc. (U.S),Saneron CCEL Therapeutics, Inc. (U.S),StemGenex (U.S),Vericel Corporation.(U.S),Cytori Therapeutics Inc.(U.S.),MolMed S.p.A. (Italy).

Regions Covered in the Personalized Cell Therapies Market:

Global Personalized Cell Therapies Market report is a comprehensive study of the global market and has been recently added by PrecisionBusinessInsights to its extensive database. Augmented demand for the global market has been increased in the last few years. This informative research report has been scrutinized by using primary and secondary research. The Global Personalized Cell Therapies Market is a valuable source of reliable data including data of the current market.

Request Free Customization copy of this report athttps://www.precisionbusinessinsights.com/request-customisation?product_id=17290&utm_source=cole&utm_medium=24

This research report represents a 360-degree overview of the competitive landscape of the Global Personalized Cell Therapies Market. Furthermore, it offers massive data relating to recent trends, technological, advancements, tools, and methodologies. The research report analyzes the Global Personalized Cell Therapies Market in a detailed and concise manner for better insights into the businesses.

The research study has taken the help of graphical presentation techniques such as infographics, charts, tables, and pictures. It provides guidelines for both established players and new entrants in the Global Personalized Cell Therapies Market.

The detailed elaboration of the Global Personalized Cell Therapies Market has been provided by applying industry analysis techniques such as SWOT and Porters five-technique. Collectively, this research report offers a reliable evaluation of the global market to present the overall framework of businesses.

Key Features of the Report:

The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porters Five Force Analysis in addition to recent technology advancements and innovations in the market.

What is the Impact of Covid-19 Outbreak on the Personalized Cell Therapies?

About Us:

Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights. We at Precision Business Insights are passionate about market research and love to do the things in an innovative way. Our team is a big asset for us and great differentiating factor. Our company motto is to address client requirements in the best possible way and want to be a part of our client success. We have a large pool of industry experts and consultants served a wide array of clients across different verticals. Relentless quest and continuous endeavor enable us to make new strides in market research and business consulting arena.

Contact Us:

[emailprotected]

PH +1-866-598-1553

View original post here:

Personalized Cell Therapies Market to Show Incredible Growth by 2025 - Owned

Nerve Repair and Regeneration Market worth $9.7 billion by 2025 – Exclusive Report by MarketsandMarkets – PRNewswire

Posted on by

CHICAGO, Aug. 4, 2020 /PRNewswire/ -- According to the new market research report "Nerve Repair and Regeneration Marketby Products (Nerve Conduits, Nerve Wraps, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Spinal Cord Stimulation, TENS, TMS), Application (Neurorrhaphy, Nerve Grafting, Stem Cell Therapy) and Region - Global Forecast to 2025", published by MarketsandMarkets,the global Nerve Repair and Regeneration Marketsize is projected to reach USD 9.7 billion by 2025 from USD 6.3 billion in 2020, growing at a CAGR of 9.1% from 2020 to 2025.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=883

The Growth in Nerve Regeneration Marketis driven mainly by high incidence of nerve injuries, the growing prevalence of neurological disorders, and rising government support for neurologic disorder research.

Neurostimulation and Neuromodulation Devices accounted for the largest share of the market, by product, in 2019

By product, the nerve repair market is segmented into neurostimulation and neuromodulation devices and biomaterials. The neurostimulation and neuromodulation devices segment is segment is expected to grow at the highest growth rate during the forecast period. The large market share of this segment is driven mainly by rising government expenditure for neurologic disorders, and favorable reimbursement .

Browsein-depth TOC on"Nerve Repair and Regeneration Market"

142 Tables 43 Figures 167 Pages

By neurostimulation and neuromodulation application, internal neurostimulation and neuromodulation accounted for the largest market share in 2019

Based on the neurostimulation and neuromodulation application , the Nerve Regeneration Market is segmented the neurostimulation and neuromodulation devices market is segmented into internal neurostimulation and neuromodulation applications and external neurostimulation and neuromodulation applications. The internal neurostimulation and neuromodulation segment is estimated to register the highest CAGR during the forecast period. This can primarily be attributed to the increasing incidence of neurological disorders across the globe.

By Biomaterials application, direct nerve repair/neurorrhaphy accounted for the largest market share in 2019

Based on application, the biomaterials market is segmented into direct nerve repair/neurorrhaphy, nerve grafting, and stem cell therapy. In 2019, the direct nerve repair segment accounted for the largest share of the market. This can be attributed to the increasing incidence of neurological disorders across the globe.

Get 10% Customization on this Research Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=883

North America was the largest regional market for Nerve Repair Market in 2019

The Nerve Repair And Regeneration Market is segmented into five major regions, namely, Europe, North America, the Asia Pacific, Latin America, and Middle East & Africa. In 2019, North America accounted for the largest share of the Nerve Regeneration Market, followed by Europe. The rising incidence of neurological disorders, favorable reimbursement policies, and the strong presence of industry players in the region are the major factors driving the growth of the market in North America.

Some of the major players operating in the global Nerve Repair And Regeneration Market include Medtronic, PLC. (Ireland), Boston Scientific Corporation (US), Abbott Laboratories (US), AxoGen, Inc. (US), Baxter International, Inc. (US), LivaNova, PLC. (UK), Integra LifeSciences (US), Polyganics (Netherlands), NeuroPace, Inc. (US), Soterix Medical, Inc. (US), Nevro Corp (US), Synapse Biomedical, Inc. (US), Aleva Neurotherapeutics (Switzerland), Collagen Matrix, Inc. (US), KeriMedical (Switzerland), BioWave Corporation (US), NeuroSigma (US), tVNS Technologies GmbH(Germany), and GiMer Medical (Taiwan).

Browse Adjacent Markets:Medical Devices Market Research Reports & Consulting

Get Special Pricing on Bundle Reports: https://www.marketsandmarkets.com/RequestBundleReport.asp?id=883

Browse Related Reports:

Neuromodulation Marketby Technology- Internal (Deep Brain Stimulation, Vagus Nerve Stimulation), External (Transcranial Magnetic Stimulation), Application (Ischemia, Chronic Pain, Parkinson's, Depression, Tremor, Epilepsy, Migraine) - Global Forecast to 2025

https://www.marketsandmarkets.com/Market-Reports/neurostimulation-devices-market-921.html

Neurodiagnostics Marketby Product (Diagnostic & Imaging Systems (MRI, Ultrasound), Clinical Testing (PCR, NGS), Reagents & Consumables), Disease Pathology (Epilepsy, Stroke), End User, and Region - Global Forecast to 2024

https://www.marketsandmarkets.com/Market-Reports/neurodiagnostics-market-229090425.html

About MarketsandMarkets

MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish MehraMarketsandMarkets INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: [emailprotected]Research Insight: https://www.marketsandmarkets.com/ResearchInsight/nerve-repair-regeneration-market.aspVisit Our Website: https://www.marketsandmarkets.comContent Source: https://www.marketsandmarkets.com/PressReleases/nerve-repair-regeneration.asp

SOURCE MarketsandMarkets

Read more here:

Nerve Repair and Regeneration Market worth $9.7 billion by 2025 - Exclusive Report by MarketsandMarkets - PRNewswire

Global Stem Cell Therapy Market 2020: Growth, Demand, Service, Types, Applications, Key Players and Industry Forecast till 2025 – Chelanpress

Posted on by

Global Stem Cell Therapy Market Analysis with forecast period 2020 to 2025 provides an in-depth analysis of market growth factors, future assessment, country-level analysis, Stem Cell Therapy industry distribution, and competitive landscape analysis of major industry players. The research report of global Stem Cell Therapy market report offers the extensive information about the top most makers and sellers who are doing great and are directly working right in the market now and which have great market area according to the country and region and other aspects that affect the growth of any company or industry. The report exhibits both Stem Cell Therapy market quantitative as well as qualitative data with tables and figures displayed in the form of bar graphs, and pie charts.

A leading research firm, Adroit Market Research added a latest industry report on Global Stem Cell Therapy Market consisting of 110+ pages during the forecast period and Stem Cell Therapy Market report offers a comprehensive research updates and information related to market growth, demand, opportunities in the Market.

Get sample copy of Stem Cell Therapy Market report @https://www.adroitmarketresearch.com/contacts/request-sample/691

Global Stem Cell Therapy market study includes a thorough analysis of the overall competitive landscape and the company profiles of leading market players involved in the global Stem Cell Therapy market. Moreover, crucial specifics such as growth drivers as well as the expected growth rate of the Stem Cell Therapy market during the forecast period are included in the report. The report also details the potential growth aspects along with the restraints of this industry vertical. Further, the presented study offers accurate insights pertaining to the different segments of the global Stem Cell Therapy market such as the market share, value, revenue, and how each segment is expected to fair post the COVID-19 pandemic.

Read complete report with TOC at:https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market

Global Stem Cell Therapy market report estimates the revenue, industry size, types, applications, players share, production volume, and consumption to get an understanding of the demand and supply chain of the market. The report encompasses technical data, raw materials, volumes, and manufacturing analysis of the global Stem Cell Therapy market. The research study delivers future projections for prominent opportunities based on the analysis of the subdivision of the market. The study meticulously unveils the market and contains substantial details about the projections with respect to industry, remuneration forecast, sales graph, and growth prospects over the forecast timeline.

Global Stem Cell Therapy market is segmented based by type, application and region.

Based on Type, the market has been segmented into:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

Based on application, the market has been segmented into:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

The market overview section highlights the Stem Cell Therapy Market definition, taxonomy, and an overview of the parent market across the globe and region wise. To provide better understanding of the global Stem Cell Therapy Market, the report includes in-depth analysis of drivers, restraints, and trends in all major regions namely, Asia Pacific, North America, Europe, Latin America and the Middle East & Africa, which influence the current market scenario and future status of the global Stem Cell Therapy Market over the forecast period.

Key Highlights Questions of Stem Cell Therapy Market:What will be the size of the global Stem Cell Therapy market in 2025?Which product is expected to show the highest market growth?Which application is projected to gain a lions share of the global Stem Cell Therapy market?Which region is foretold to create the most number of opportunities in the global Stem Cell Therapy market?Will there be any changes in market competition during the forecast period?Which are the top players currently operating in the global Stem Cell Therapy market?

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691

About Us :Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Read more from the original source:

Global Stem Cell Therapy Market 2020: Growth, Demand, Service, Types, Applications, Key Players and Industry Forecast till 2025 - Chelanpress

17 new coronavirus cases have been reported in Maine – Bangor Daily News

Posted on by

Another 17 cases of the new coronavirus have been detected in Maine, health officials said Sunday.

Sundays report brings the total coronavirus cases in Maine to 4,042. Of those, 3,625 have been confirmed positive, while 417 were classified as probable cases, according to the Maine Center for Disease Control and Prevention.

New cases were reported in Piscataquis (1), Sagadahoc (1), Washington (1), Androscoggin (5), Cumberland (6) and York (3) counties, state data show.

The agency revised Saturdays cumulative total to 4,025, down from 4,026, meaning there was a net increase of one over the previous days report, state data show. As the Maine CDC continues to investigate previously reported cases, some are determined to have not been the coronavirus, or coronavirus cases not involving Mainers. Those are removed from the states cumulative total.

No new deaths were reported Sunday, leaving the statewide death toll at 125. Nearly all deaths have been in Mainers over age 60.

So far, 393 Mainers have been hospitalized at some point with COVID-19, the illness caused by the coronavirus. Of those, nine are currently hospitalized, with three in critical care and one on a ventilator.

Our charts tracking the numbers of active cases, recoveries and deaths both statewide and by county are updated daily.

Meanwhile, eight more people have recovered from the coronavirus, bringing total recoveries to 3,512. That means there are 405 active and probable cases in the state, which is up from 397 on Saturday.

A majority of the cases 2,222 have been in Mainers under age 50, while more cases have been reported in women than men, according to the Maine CDC.

As of Sunday, there have been 191,921 negative test results out of 197,666 overall. Just over 2.5 percent of all tests have come back positive, Maine CDC data show.

The coronavirus has hit hardest in Cumberland County, where 2,088 cases have been reported and where the bulk of virus deaths 69 have been concentrated. It is one of four counties the others are Androscoggin, Penobscot and York, with 563, 152 and 673 cases, respectively where community transmission has been confirmed, according to the Maine CDC.

There are two criteria for establishing community transmission: at least 10 confirmed cases and that at least 25 percent of those are not connected to either known cases or travel. That second condition has not yet been satisfied in other counties.

Other cases have been reported in Aroostook (33), Franklin (45), Hancock (35), Kennebec (170), Knox (27), Lincoln (35), Oxford (53), Piscataquis (4), Sagadahoc (56), Somerset (33), Waldo (62) and Washington (13) counties.

As of Sunday morning, the coronavirus has sickened 4,998,802 people in all 50 states, the District of Columbia, Puerto Rico, Guam, the Northern Mariana Islands and the U.S. Virgin Islands, as well as caused 162,430 deaths, according to Johns Hopkins University of Medicine.

View post:

17 new coronavirus cases have been reported in Maine - Bangor Daily News

Everything you need to know about coronavirus in Arizona Aug. 9 – 12news.com KPNX

Posted on by

In an effort to track the changes with the coronavirus outbreak in Arizona, 12 News has started a daily live blog.

ARIZONA, USA In an effort to track the changes with the coronavirus outbreak in Arizona, 12 News has started a daily live blog.

Here is the live blog for Sunday, Aug. 9.

COVID-19 cases reported in Arizona on Sunday

There have been186,923confirmed cases of coronavirus and4,150coronavirus-related deaths reported in Arizona, according to the state's latest numbers.

That is an increase from 186,107cases and 4,137 coronavirus-related deaths reported as of Saturday.

A week ago, there were 178,467cases and3,765deaths reported in Arizona.

Arizona sets virus spread guidelines for school reopenings

Arizona officials have released a series of guidelines that public schools are urged to use when deciding whether its safe to reopen for full in-person learning.

But state health director Dr. Cara Christ said Thursday that it is going to be several weeks before any county meets those benchmarks.

The scientific guidelines released by Christ and schools chief Kathy Hoffman lay out three key measurements of the virus community effects.

They are just guidelines, and school districts wont be required to follow them.

But Hoffman discouraged school districts from deviating and said voters should hold their school boards accountable if they ignore the guidance.

The above article is from The Associated Press.

Mohave County coronavirus case update

The Mohave County Health Department confirmed 15 new cases today. Three new deaths have also been reported since the last update.

There are now 3,180 positive cases total in Mohave County and 158 total deaths.

The average age of positive cases is 48.4 years old.

Free masks available for some Arizonans

The Arizona Department of Health Services announced that some Arizonans would be able to get free masks from the state.

The department partnered with Hanes to provide free face masks to Arizonas most vulnerable populations.

Anyone who is part of a vulnerable population (including, but not limited to, individuals with medical conditions or individuals age 65 or older) is able to get a free mask.

Each other will provide five washable, reusable cloth face masks, one order per household.

The department hopes to give out two million cloth face masks.

Anyone with questions can visit the department's FAQs page or contact Hanes at 1-800-503-6698.

Arizona releases ZIP code locations of coronavirus cases, other data

The Arizona Department of Health Services has released expanded data points regarding coronavirus cases in the state.

The AZDHS website now features the location of confirmed cases in Arizona by zip code.

You can see the current ZIP code map hereand can find yours by clicking around or searching for your ZIP code in the top right of the map.

More information on coronavirus cases from Sunday

There have been 186,923 confirmed cases of coronavirus in Arizona and 4,150 coronavirus-related deaths as of Sunday.

That is an increase from 186,107 cases and 4,137 coronavirus-related deaths reported as of Saturday.

There were 816 new cases reported on Sunday, a decrease from the 1,054 new cases reported on Saturday.

There were 13 new deaths reported on Sunday, a decrease from the 56 new deaths reported on Saturday.

There were 5,479 cases reported on the collection date of June 29, the day with the most collected diagnoses so far. That is subject to change.

Health officials said the days with the highest number of reported deaths was July 15 and 17, when 85 people died each day. That is subject to change.

In total, 7,632 new tests were reported on Sunday, an increase from the 13,040 new tests reported on Saturday.

There have been a total of 1,260,660 PCR and Serology tests reported to the state as of Sunday.

12.5% of those tests have been positive as of Sunday, the same as Saturday.

Here's a county breakdown:

COVID-19 is believed to be primarily spread through coughs or sneezes.

It may be possiblefor the virus to spread by touching a surface or object with the virus and then a person touching their mouth, nose or eyes, but this is not thought to be the main method of spread, the CDC says.

You should consult your doctor if you traveled to an area currently affected by COVID-19 and feel sick with fever, cough or difficulty breathing.

There is no vaccine for the coronavirus, so the best way to prevent COVID-19 and other respiratory diseases is to:

You can text FACTS to 602-444-1212 to receive more information on the coronavirus and to ask questions.

See more here:

Everything you need to know about coronavirus in Arizona Aug. 9 - 12news.com KPNX

Coronavirus in N.Y.C.: Heres What Happened This Week – The New York Times

Posted on by

Weather: Showers and possibly heavy thunderstorms, with a high in the upper 70s. Scattered storms Saturday afternoon, but Sunday should be mostly sunny.

Alternate-side parking: In effect until Aug. 15 (Feast of the Assumption). Read about the amended regulations here.

As fall looms, New York is continuing to stem its coronavirus outbreak. This week, only about 1 percent of tests each day in the city were positive. Statewide, hospitalizations for the virus have hit new lows.

Still, New York City and its suburbs are grappling with how to head off a potential second wave when the weather turns colder and people retreat indoors. And just days ago, Dr. Oxiris Barbot resigned as the citys health commissioner, citing her disappointment with Mayor Bill de Blasios handling of the virus crisis.

Heres what else happened this week:

The city said it was aiming to safely reopen schools this fall because New York has maintained a low infection rate.

But a torrent of logistical issues and political problems could upend that plan.

Mr. de Blasios proposal includes safety measures such as having children report to school one to three days a week with masks and social distancing required. But that hasnt quelled the fears of some parents who saw their neighborhoods ravaged by the virus, and some teachers are threatening a sickout.

Many large districts in the country are starting their school years fully remote. In finalizing plans for New York City, officials are weighing factors including the past failures of online learning; examples of the virus rapidly coming through school doors; and the potential for a child care crisis.

The mayor said he was using the citys sheriffs office to inform travelers about the states mandatory quarantine rules.

Mr. de Blasio announced this week that drivers would be stopped at traveler registration checkpoints at bridges and tunnels, and that people from places on New York States required quarantine list would be asked to fill out forms detailing their travel.

But the authorities wont be stopping every car. They also most likely wont be at the same locations on any given day. And the sheriffs office cant force travelers to comply with the 14-day quarantine.

Some elected officials have criticized the plan, saying they do not believe that checkpoints would be effective. Others have raised concerns about privacy risks.

The delay in counting votes for New Yorks primary raised concerns about conducting elections during the pandemic.

It took six weeks for Representative Carolyn B. Maloney and Councilman Ritchie Torres to be declared the winners in their races.

After Gov. Andrew M. Cuomo ordered a wide expansion of absentee voting this year because of the coronavirus, New York City received a deluge of 400,000 mail-in ballots. Nearly a month and a half after the June primary, some of those votes were still being counted.

Officials cited several problems with the primary. Thousands of ballots were mailed out only a few days before the election, not giving voters time to return them. There werent enough staff members to tally the votes. Also, the Postal Service apparently had trouble processing the ballots prepaid return envelopes, which may have caused an unknown number of votes to be wrongfully disqualified.

Now, some candidates and political analysts fear that what occurred in New York could happen nationally in November, creating a nightmare situation.

Updated Aug. 8, 2020

The latest highlights as the first students return to U.S. schools.

President Trump has also jumped into the fray, repeatedly citing the New York primary for his unfounded claims that mail-in voting is susceptible to fraud.

Outages Pile on Misery for 1.4 Million Coping With Pandemic

Violence at Rikers at an All-Time High Despite Citys Promise to Curb It

New York Attorney General Sues N.R.A. and Seeks Its Closure

When the Bronx Was a Forest: Stroll Through the Centuries

Want more news? Check out our full coverage.

The Mini Crossword: Here is todays puzzle.

New Yorks moratorium on evictions was extended until September as many tenants continued to struggle to pay rent. [New York Post]

Nearly 20 police unions are suing New York City over lawmakers ban on the use of chokeholds. [Daily News]

What were watching: The Times Metro reporters J. David Goodman and Matthew Haag discuss New Yorks road to economic recovery on The New York Times Close Up With Sam Roberts. The show airs on Friday at 8 p.m., Saturday at 1:30 p.m. and Sunday at 12:30 p.m. [CUNY TV]

The Timess Melissa Guerrero writes:

Although most performance spaces, museums and community centers are closed, people are finding creative ways to connect through virtual events and programs. Here are suggestions for maintaining a New York social life this weekend while keeping a safe distance from other people.

On Friday at 5 p.m., as part of the Strong Like a Mama summit, a panel of obstetrician-gynecologists and other experts, including Dr. Taraneh Shirazian from N.Y.U. Langone Health, will hold a discussion about maternal mortality rate and access to quality maternal care.

Register on the event page.

On Saturday at noon, the author and historian Jason Antos will lead a virtual outing highlighting religious diversity in Flushing, Queens. The tour will start at the Quaker Meeting House and end at the Hindu Temple (Hindu Temple Society of North America).

R.S.V.P. on the event page to watch the livestream.

On Saturday at 12:30 p.m., learn about two of the most-used commuter rail systems in the United States without leaving your couch. Sam Angelillo, a New York Transit Museum educator, will host a talk about the history of the railways and their importance in connecting the city to its suburbs.

To attend the livestream, register on the event page.

Its Friday T.G.I.F.

Dear Diary:

My wife and I came to New York in November 2002 for my second New York City Marathon. We splurged and booked a room at a boutique hotel near the New York Public Library, where runners board early morning buses that take them to where the race starts on Staten Island.

We registered at the desk with an assistant manager, who struck us as the type of well-mannered, middle-age gentleman one might encounter at a traditional European hotel.

I made conversation by mentioning the huge number of international runners I had seen. He volunteered that he was from what had been known as Czechoslovakia. We fell into an easy, extended chat about distance running.

Eventually, he insisted on personally showing us to the room we had booked on a lower floor. He seemed intent on continuing our conversation.

As he pulled our luggage trolley onto the elevator, a twinkle came to his eyes.

I bet you dont know the name of the greatest Czech distance runner of all time, he said.

Somehow, my usually unreliable memory jumped to life.

Um, yeah, Emil Zatopek, I stammered.

His face lit up, and he beamed with pride.

After a moments reflection, he spoke again.

The room you reserved just isnt right for you, he said. Allow me to upgrade you to a larger suite on an upper floor.

Geoffrey Vincent

New York Today is published weekdays around 6 a.m. Sign up here to get it by email. You can also find it at nytoday.com.

Were experimenting with the format of New York Today. What would you like to see more (or less) of? Post a comment or email us: nytoday@nytimes.com.

Visit link:

Coronavirus in N.Y.C.: Heres What Happened This Week - The New York Times

What you need to know about coronavirus Sunday, Aug. 9 – KING5.com

Posted on by

Find developments on the COVID-19 pandemic and the plan for recovery in the U.S. and Washington state.

Where cases stand in Washington

The United States' failure to contain the spread of the coronavirus has been met with astonishment and alarm in Europe, as the world's most powerful country surpassed a global record of 5 million confirmed infections on Sunday, according to a count by Johns Hopkins University.

As Axios reports, former FDA commissioner Scott Gottlieb has sent out a warning, saying that the death toll will "definitely" reach between 200,000 and 300,000 by the end of this year.

Perhaps nowhere outside the U.S. is America's bungled virus response viewed with more consternation than in Italy, which was ground zero of Europe's epidemic. Italians were unprepared when the outbreak exploded in February and the country still has one of the world's highest official death tolls at 35,000. Read more

Updatedguidelines for fitness centers and gyms in our state take effect August 10, and some gym owners say they are too strict.

Among the changes is a 300-square-foot amount of space per participant for any indoor fitness activities. While larger gyms may be able to manage that, smaller gyms and studios could be faced with hard decisions. Read more

A person tested positive for COVID-19 after attending a wedding ceremony in Kittitas County earlier this month and now health officials are trying to notify everyone in attendance so they can get tested.

The wedding was held Sunday, August 2 at the Cattle Barn Ranch wedding venue in Cle Elum, according to a release from the Kittitas County Incident Management Team (IMT).

The ceremony was held outdoors with 100 people in attendance, and there was a reception, said Dr. Mark Larson, Kittitas County health officer.

For pandemic jobless, the only real certainty is uncertainty. Read more

Go here to see the original:

What you need to know about coronavirus Sunday, Aug. 9 - KING5.com